There has been significant recent interest in the development of highly fluorescent nanomaterials as contrast agents for optical imaging in vivo. 1 The imaging agents should ideally be bright, nontoxic, biocompatible, and stable against photobleaching. Among the extensively studied are those based on semiconductor quantum dots (QDs) such as CdSe/ZnS. 2 The rationale for the use of QDs over conventional organic dyes is now generally accepted in the literature. 3 There are already successful in vivo imaging demonstrations of QDs on tumor vasculature, tumor-specific membrane antigens, sentinel lymph nodes, etc. 2,4 The semiconductor QDs containing cadmium or other heavy metals are unfortunately known for their significant toxicity even at relatively low concentrations, 5,6 which may prove prohibitive to any patient studies. Therefore, the search for benign alternatives has continued. Of particular interest and significance was the recent finding that small carbon nanoparticles could be surface-passivated by organic or bio-molecules to become strongly fluorescent. 7 These fluorescent carbon nanoparticles, 7,8 dubbed "carbon dots" (C-Dots, Scheme 1), were found to be physicochemically and photochemically stable and non-blinking. The carbon particle core could also be doped with an inorganic salt such as ZnS before the surface functionalization to significantly enhance the fluorescence brightness (C ZnS -Dots, Scheme 1). 9 These carbon dots have been successfully used for in vitro cell imaging with both one-and two-photon excitations. 7,9,10 Carbon is hardly considered as an intrinsically toxic element. Available results from the ongoing toxicity evaluation of the oligomeric PEG-functionalized C-Dots 7 in mice have suggested no meaningful toxic effects, 11 raising the prospect for in vivo biocompatibility and uses of carbon dots. Here we report the first study of carbon dots for optical imaging in vivo. The results suggest that the carbon dots are not only brightly fluorescent in solution, as reported previously, 7,9 but also well-behaved as contrast agents in live mice.The C-Dots and C ZnS -Dots with the PEG diamine, H 2 NCH 2 (CH 2 CH 2 O) n CH 2 CH 2 CH 2 NH 2 (n ∼ 35, PEG 1500N ), as the surface passivation agent were prepared and characterized as previously reported. 7,9,10 Shown in Figure 1 For subcutaneous injection, female DBA/1 mice (∼25 g) were shaved in the back area surrounding the injection point. Upon the injection of a C-Dots solution (30 µg carbon coreequivalent in 30 µL) or a C ZnS -Dots solution (65 µg in 30 µL), the mice were imagined in a Lumazone FA in vivo Imaging System (MAG Biosystems) with 470 nm (FWHM ∼ 40 nm) excitation and 525 nm (FWHM ∼ 47 nm) emission filters. As shown in Figure 2, the fluorescence images of the subcutaneously injected mice exhibited bright emissions from CDots and C ZnS -Dots. The relatively stronger fluorescence from the latter is consistent with the previously reported solution-phase results. 9 The injected carbon dots in mice diffused relatively slowly, with the ...

No abstract

Fluorescent carbon dots (small carbon nanoparticles with the surface passivated by oligomeric PEG molecules) were evaluated for their cytotoxicity and in vivo toxicity and also for their optical imaging performance in reference to that of the commercially supplied CdSe/ZnS quantum dots. The results suggested that the carbon dots were biocompatible, and their performance as fluorescence imaging agents was competitive. The implication to the use of carbon dots for in vitro and in vivo applications is discussed.

No abstract

Both all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) have proven to be very effective in obtaining high clinical complete remission (CR) rates in acute promyelocytic leukemia (APL), but they had not been used jointly in an integrated treatment protocol for remission induction or maintenance among newly diagnosed APL patients. In this study, 61 newly diagnosed APL subjects were randomized into three treatment groups, namely by ATRA, As 2O3, and the combination of the two drugs. CR was determined by hematological analysis, tumor burden was examined with real-time quantitative RT-PCR of the PML-RAR␣ (promyelocytic leukemia-retinoic acid receptor ␣) fusion transcripts, and side effects were evaluated by means of clinical examinations. Mechanisms possibly involved were also investigated with cellular and molecular biology methods. Although CR rates in three groups were all high (>90%), the time to achieve CR differed significantly, with that of the combination group being the shortest one. Earlier recovery of platelet count was also found in this group. The disease burden as reflected by fold change of PML-RAR␣ transcripts at CR decreased more significantly in combined therapy as compared with ATRA or As2O3 mono-therapy (P < 0.01). This difference persisted after consolidation (P < 0.05). Importantly, all 20 cases in the combination group remained in CR whereas 7 of 37 cases treated with mono-therapy relapsed (P < 0.05) after a follow-up of 8 -30 months (median: 18 months). Synergism of ATRA and As2O3 on apoptosis and degradation of PML-RAR␣ oncoprotein might provide a plausible explanation for superior efficacy of combinative therapy in clinic. In conclusion, the ATRA͞As2O3 combination for remission͞ maintenance therapy of APL brings much better results than either of the two drugs used alone in terms of the quality of CR and the status of the disease-free survival.A cute promyelocytic leukemia (APL) accounts for 10-15% of acute myeloid leukemia in which the maturation of granulocytic cells was blocked at the promyelocytic stage. It is also characterized by the t(15;17)(q22;q21) chromosome translocation generating the PML-RAR␣ (promyelocytic leukemia-retinoic acid receptor ␣) fusion gene, of which the leukemogenic role has been demonstrated by the transgenic mouse models (1). Although conventional chemotherapy such as anthracyclines and cytosine arabinoside (ara-C) succeeded in two-thirds of APL patients in obtaining complete remission, high frequency of early death mainly due to exacerbation of bleeding syndrome and low 5-year diseasefree survival (DFS) rates dwarf them to new drugs (2). Our group in the Shanghai Institute of Hematology (SIH) has long been interested in differentiation therapy of human cancers, as inspired by the Chinese philosophy that it is better to transform a bad element instead of simply getting rid of it. After the discovery in the 1970s to early 1980s showing that some leukemic cells could undergo phenotypic reversion under differentiation inducers (3, 4), we started to screen a...

Genomic landscapes of 92 adult and 111 pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) were investigated using next-generation sequencing and copy number alteration analysis. Recurrent gene mutations and fusions were tested in an additional 87 adult and 93 pediatric patients. Among the 29 newly identified in-frame gene fusions, those involving MEF2D and ZNF384 were clinically relevant and were demonstrated to perturb B-cell differentiation, with EP300-ZNF384 inducing leukemia in mice. Eight gene expression subgroups associated with characteristic genetic abnormalities were identified, including leukemia with MEF2D and ZNF384 fusions in two distinct clusters. In subgroup G4 which was characterized by ERG deletion, DUX4-IGH fusion was detected in most cases. This comprehensive dataset allowed us to compare the features of molecular pathogenesis between adult and pediatric B-ALL and to identify signatures possibly related to the inferior outcome of adults to that of children. We found that, besides the known discrepancies in frequencies of prognostic markers, adult patients had more cooperative mutations and greater enrichment for alterations of epigenetic modifiers and genes linked to B-cell development, suggesting difference in the target cells of transformation between adult and pediatric patients and may explain in part the disparity in their responses to treatment.

Graphene oxide (GO) is a highly effective absorbent of methylene blue (MB) and can be used to remove MB from aqueous solution. A huge absorption capacity of 714 mg/g is observed. At initial MB concentrations lower than 250 mg/L, the removal efficiency is higher than 99% and the solution can be decolorized to nearly colorless. The removal process is fast and more efficient at lower temperatures and higher pH values. The increase of ionic strength and the presence of dissolved organic matter would further enhance the removal process when MB concentration is high. The results indicate that GO can be applied in treating industrial effluent and contaminated natural water. The implications to graphene-based environmental technologies are discussed.

No abstract